Bristol-Myers to Buy Rights to Hep C Drug

ZymoGenetics(ZGEN Quote) has landed Bristol-Myers Squibb(BMY Quote) as its worldwide development partner for PEG-Interferon lambda, a new experimental treatment for hepatitis C.

Bristol-Myers has agreed to pay $85 million upfront to ZymoGenetics for rights to PEG-Interferon lambda, which is currently in phase I studies. Bristol-Myers will pay another $20 million license fee to ZymoGenetics in 2009, the companies announced Monday.

Long-acting interferons taken by weekly injection, sold by Schering-Plough(SGP Quote) and Roche, are a current mainstay of hepatitis C treatment, but the drugs produce flu-like symptoms among other side effects and are generally not tolerated well by patients.

Early data generated by PEG-Interferon lambda and presented at a hepatitis C conference in the fall suggested the drug might be safer and better tolerated than the current long-acting interferons.

ZymoGenetics and Bristol-Myers will co-develop PEG-Interferon lambda in the U.S. and Europe, and the two companies will share development costs. ZymoGenetics said it could be entitled to additional payments from Bristol-Myers of up to $430 million based on pre-defined development and regulatory milestones for the drug in hepatitis C, and $285 million in sales-based milestone payments.

If PEG-Interferon lambda can be developed to treat other diseases, Bristol-Myers may pay ZymoGenetics another $287 million in milestone payments.

While long-acting interferon plus the drug ribavirin are the current standard of care for hepatitis C patients, the treatment market is evolving with the development of new and novel drugs from companies like Vertex Pharmaceuticals(VRTX Quote), Pharmasset(VRUS Quote), Schering-Plough and InterMune(ITMN Quote). Updated from 4:01 p.m. EST

Moreover, ZymoGenetics is not the only company seeking to develop an alternative to the current long-acting interferons. Human Genome Sciences(HGSI Quote) is in the midst of a phase III study program for Albuferon, a long-acting interferon that can be administered twice a month instead of weekly. Results from the Albuferon studies are expected in March.